Proactive Investors - Run By Investors For Investors

MaxCyte's latest deal 'a perfect relationship' says CEO Doug Doerfler

MaxCyte Inc (LON:MXCT) chief executive Doug Doerfler tells Proactive: ''This is the second relationship we have inked using our CARMA platform''.

CARMA retrains the cells found in blood to attack cancer.

The AIM-listed life sciences group is teaming up with Washington University in St Louis and will use CARMA to develop immunotherapy drug candidates.

  NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use